1036 ET - Merck's struggles with Gardasil aren't easing up. The drug maker disclosed 1Q sales of the treatment, which prevents cancers caused from the human papillomavirus, declined 41% to $1.33 billion, due primarily to lower demand in China. Gardasil's challenges were on display in the prior quarter when the company's guidance came up short of Wall Street's estimates and said it was pausing shipments to China of the treatment from February through at least the middle of the year. Gardasil is Merck's biggest-selling franchise behind blockbuster cancer therapy Keytruda, which saw sales increase 4% to $7.21 billion in the quarter. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
April 24, 2025 10:36 ET (14:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.